Itraconazole: Triazole Antifungal Agent for CYP3A4 and Candida Research

Executive Summary: Itraconazole (CAS: 84625-61-6) is a triazole antifungal agent acting primarily via potent inhibition of cytochrome P450 enzyme CYP3A4, with documented in vitro IC50 as low as 0.016 mg/L against Candida glabrata and Candida kefyr (APExBIO). Its bioactive metabolites retain or exceed parental potency (https://p-450.com/index.php?g=Wap&m=Article&a=detail&id=45). Itraconazole also blocks hedgehog signaling and angiogenesis, extending its application to studies of drug metabolism, fungal infection, and resistance mechanisms. PP2A-regulated autophagy is a key factor in Candida albicans biofilm drug resistance, providing a context for itraconazole mechanistic studies (Shen et al., 2025). APExBIO’s Itraconazole (SKU B2104) is a validated reference for reproducible antifungal, drug interaction, and translational research.

Biological Rationale

Candida species, including C. albicans, C. glabrata, and C. kefyr, are leading causes of opportunistic fungal infections in immunocompromised populations (Shen et al., 2025). Biofilm formation is a major virulence factor and confers intrinsic resistance to most antifungal agents. The cytochrome P450 (CYP) enzyme family, especially CYP3A4, is central to the oxidative metabolism of azole antifungals and many co-administered drugs. Inhibition of CYP3A4 can modulate drug efficacy, toxicity, and resistance. Itraconazole, a triazole antifungal, uniquely combines high antifungal potency with strong CYP3A4 inhibition, supporting its dual role as both a therapeutic and research tool (see also).

Mechanism of Action of Itraconazole

Itraconazole inhibits ergosterol biosynthesis by targeting lanosterol 14α-demethylase (CYP51), an essential fungal CYP450 enzyme. Inhibition leads to depletion of ergosterol and accumulation of toxic 14α-methylated sterols, impairing fungal cell membrane integrity (APExBIO). Additionally, itraconazole acts as a substrate and potent inhibitor of human CYP3A4, affecting drug metabolism and interaction studies (see also). Oxidative metabolism produces active hydroxylated, keto, and N-dealkylated derivatives, which can further inhibit fungal and mammalian CYPs. Itraconazole also inhibits the hedgehog signaling pathway and angiogenesis, broadening its research utility beyond antifungal applications.

Evidence & Benchmarks

• Itraconazole exhibits in vitro IC50 values as low as 0.016 mg/L against Candida glabrata and Candida kefyr under standard broth microdilution conditions (APExBIO).
• Biofilm-forming Candida albicans strains are inherently resistant to azoles due to PP2A-mediated autophagy activation, which reduces antifungal efficacy (Shen et al., 2025).
• Itraconazole is insoluble in water and ethanol, but soluble in DMSO at concentrations ≥8.83 mg/mL at 37°C or after ultrasonic bath treatment (APExBIO).
• Animal models of disseminated candidiasis show reduced fungal burden and improved survival rates with itraconazole treatment (see also).
• Itraconazole inhibits the hedgehog signaling pathway in cell-based assays, as shown by decreased GLI1 transcriptional activity (see also).

Applications, Limits & Misconceptions

Itraconazole (SKU B2104, APExBIO) is routinely used for:

• In vitro and in vivo antifungal susceptibility testing for Candida species and other fungal pathogens.
• Drug interaction studies involving CYP3A-mediated metabolism and inhibition.
• Investigations of fungal biofilm resistance mechanisms, including autophagy modulation.
• Cell-based assays probing hedgehog pathway or angiogenesis inhibition.

Compared to earlier guides (Itraconazole: Triazole Antifungal Agent and CYP3A4 Inhibitor), this dossier provides additional clarity on PP2A/autophagy roles and workflow-specific solubility/storage parameters.

Common Pitfalls or Misconceptions

• Itraconazole is not effective against non-fungal pathogens (e.g., bacteria or viruses).
• Insolubility in water/ethanol limits direct use in aqueous applications; DMSO is required for dissolution.
• Biofilm-associated Candida strains with induced autophagy may display reduced sensitivity, necessitating combination or alternative strategies (Shen et al., 2025).
• Long-term storage in solution is not recommended; aliquots should be stored at -20°C in solid form (APExBIO).
• Itraconazole’s CYP3A4 inhibition may confound metabolic studies unless thoroughly controlled.

Workflow Integration & Parameters

APExBIO's Itraconazole (SKU B2104) is supplied as a solid (MW 705.63, chemical formula C₃₅H₃₈Cl₂N₈O₄). For optimal handling:

• Dissolve in DMSO at ≥8.83 mg/mL; warm to 37°C or use ultrasonic bath for maximal solubility.
• Prepare working solutions immediately prior to use; avoid prolonged exposure to light or air.
• Store aliquots at -20°C; avoid repeated freeze-thaw cycles.
• For in vitro assays, reference IC50 values for Candida glabrata and Candida kefyr (0.016 mg/L) for benchmarking.
• For drug interaction studies, account for CYP3A4 inhibition and potential cross-reactivity with co-administered agents.

See Itraconazole (SKU B2104): Data-Driven Solutions for Candida Research for detailed scenario-driven guidance. This article extends earlier work by mapping workflow integration with autophagy-driven resistance models and solubility/storage best practices.

Conclusion & Outlook

Itraconazole is a versatile triazole antifungal agent with a well-characterized mechanism of CYP3A4 inhibition, robust antifungal activity against Candida spp., and proven translational value for drug metabolism, resistance, and biofilm research. Its validated performance in both in vitro and in vivo models, coupled with advanced mechanistic insight into autophagy-driven resistance, positions APExBIO’s Itraconazole as a cornerstone reagent in modern antifungal and drug interaction studies. Future research should further clarify its roles in combined resistance mechanisms and translational infection models.

For additional insights on translational research applications and mechanistic cross-talk, see Itraconazole as a Translational Game-Changer—this dossier updates clinical relevance and workflow specifics for bench-to-bedside innovation.